Type 2 Diabetes

Leptin (an adipocyte-secreted hormone) has been an object of observation since 1994. Its levels in the body are roughly proportional to an individual's amount of adipose tissue. It seems to regulate energy homeostasis, decrease energy intake, and increase energy expenditure. From its discovery, researchers hoped that its manipulation could be useful clinically.

Our Nov. list includes a gastric balloon “pill,” a calculator for blindness and amputation risk, and results of the ACCORD trial and FIGHT study.

Changes in gut bacterial growth rates may be linked to onset of diseases, such as type 2 diabetes or irritable bowel syndrome, for example, according to research published in the journal Science.

When I first started seeing patients on my own, I would get annoyed when patients came in with printouts from WebMD, Health.com, or the dreaded Wikipedia.

How much time do you and your patients spend unraveling Medicare red tape? Can you relate to our blogger’s frustration?

Changes in CV risk factors, low frequency of hypoglycemic events, and a protective renal effect are a few benefits found with SGLT2 inhibitors.

Researchers sift through risk factors and clinical trial findings to determine if the SGLT2 inhibitor increases bladder cancer risk.

For overweight adults with type 2 diabetes, study results show that even light walking was linked to an average 10-point drop in blood pressure.

Type 2 diabetes drug empagliflozin significantly diminished the incidences of hospitalizations and even death from heart failure.

Study results show PCSK9 inhibitor alirocumab reduces cholesterol by increasing the fractional clearance rate of IDL and LDL.

Which GLP-1 receptor agonist showed improved HbAlc with no weight gain or hypoglycemia?

Insulin degludec went head-to-head with insulin glargine in a study of exercise-induced hypoglycemia in type 1 diabetes.

Despite the side effects experienced at a high dose, a long-acting GLP-1 agonist proceeds to phase III trials.

A new analysis of trial data shows that patients with exocrine pancreatic insufficiency benefit about as much from pancrelipase delayed-release capsules (Creon) whether or not they have diabetes mellitus.

Sleep apnea and depression are both serious conditions patients deal with on a daily basis. A recent study looked at a possible connection between the two and how doctors can better treat these patients.

There are many varieties of type 2 diabetes, a new genotype analysis shows. Tracking these genotype variations in common diseases is possible using data from electronic medical records (EMRs), according to researchers at the Icahn School of Medicine at Mount Sinai in New York City.

The much buzzed about Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial has been tracking the medication in patients with type 2 diabetes. An update on the outcomes was provided at the 10th Annual Cardiometabolic Health Congress (CMHC 2015) in Boston, Massachusetts.

Do added sugars and artificial sweeteners play an equal role in type 2 diabetes risk?

The US Preventive Services Task Force's updated recommendations on screening for diabetes type 2 have the American Medical Association's (AMA) president fuming.

Study results suggest that screening for metabolic syndrome among patients taking antipsychotic medications occurs far less frequently than recommended by the guidelines.

The evidence indicates resistant starches improve glucose metabolism beyond what would be expected from its reduced glycemic index.

Studies have shown that excessive caloric intake accelerates aging, whereas caloric restriction has been shown to lengthen lifespan and reduce the risk of several diseases.

As part of a multi-institutional effort, researchers in the fields of proteomics, lipidomics, and metabolomics will collaborate to discover more effective ways of predicting which patients with type 1 diabetes are at greater risk for developing kidney disease.

Researchers in Australia recently reported that the immune signaling protein NLRP1 plays a key role in metabolism by activating fat-burning processes when the body's energy intake is too high.

Two new drugs have hit the diabetes market, including a drug to treat both types 1 and 2, but do they have the power to change prescribing habits?

Type 1 diabetes mellitus (T1DM) is treated by necessity with insulin analogues in an attempt to mimic normal physiological insulin profiles. Regardless, this approach is rarely completely successful and most T1DM patients experience fluctuating or suboptimal glucose control, significant hypoglycemia and microvascular tissue complications.

High rates of undiagnosed diabetes in an Asian population increase other health risks as well.

Our blogger provides her assessment of recent FDA warnings on SGLT2 inhibitors.

Artificial beta cell systems and insulin pumps went head-to-head in two trials with type 1 diabetes patients.

Has the onslaught of humorous social media posts about ICD-10 been more eventful than the actual coding transition itself?